Register

Radiation Oncology

Journal Club ft. NEJM publications   

Questions discussed in this category

In light of the improved outcomes seen in patients receiving IO +/- olaparib, what role, if any, do you think pelvic radiation still plays in the management of patients with advanced endometrial cancer?
3 Answers available
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?
4 Answers available
Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?
Do you base your decision on extent of residual disease?  Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...
4 Answers available
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
Is a placebo-controlled trial anticipated?
6 Answers available
Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?
3 Answers available
What is your approach to patients with unresectable, node-negative perihilar cholangiocarcinoma who have undergone biliary stenting and have no evidence of distant disease?
If borderline resectable, can the TOPAZ regimen be considered for downstaging effects?
4 Answers available
Can adjuvant nivolumab for bladder CA as per Checkmate 274 be extrapolated for the concurrent chemoRT bladder preservation setting?
4 Answers available
How do you select neoadjuvant chemo vs chemoRT in locally advanced, resectable GEJ/esophageal tumors?
NCCN recommends perioperative FLOT or FOLFOX vs. neoadjuvant chemoRT with Carboplatin/Paclitaxel or FOLFOX.Does CM-577 and the approval of nivolumab p...
9 Answers available
Can the results of Checkmate 577 be applied to patients who do not undergo surgery following chemoradiation because of a clinical complete response?
What about for a patient with complete radiographic response who declines surgical management?
3 Answers available
Can CM577 regimen of adjuvant nivolumab s/p neoadjuvant chemoRT with residual disease following surgery be extrapolated to patients with R1 resection unable to undergo re-resection?
CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.  
3 Answers available
Should we consider radiation therapy for patients with N2 EGFRm NSCLC who will receive osimertinib, though RT was excluded on ADAURA?
Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?
4 Answers available
How do you manage patients on atezolizumab/bevacizumab with advanced HCC who develop arterial thrombosis?
Do you continue atezolizumab alone? Would you avoid anticoagulation?
6 Answers available
How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
2 Answers available
Would you use upfront atezo/bev in a patient with HCC and untreated hepatitis?
3 Answers available


Papers discussed in this category

Lancet Oncol., 2015-09-01
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
N Engl J Med, 2006 Jul 6
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
The New England journal of medicine, 2002-10-17
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
Ann. Surg., 2007-11-01
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.
N Engl J Med, 2021-04-01
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
J Clin Oncol, 2021 Apr 23
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Lancet,
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
BMC Cancer, 2016 Jul 19
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
N Engl J Med, 2020 May 14
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Liver Cancer, 2019 Sep 18
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.
N Engl J Med, 2022 Sep 12
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Front Oncol, 2023 Jan 04
Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.
Br J Dermatol, 2015 Aug 08
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.
Lancet, 1998 Jul 25
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.
Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
N Engl J Med,
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Lancet Oncol, 2021 Mar 12
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Annals of surgery, 2009-05
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.
N. Engl. J. Med.,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
JAMA oncology, 2019-06-01
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Transpl Int, 2010 May 20
Liver transplantation for cholangiocarcinoma.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Eur J Surg Oncol,
Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy.
World J Surg, 2019 Apr
Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.
J Surg Oncol, 2020 Sep 24
Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate.
World J Gastrointest Surg, 2019 Jun 27
Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature.
J. Clin. Oncol., 2018 Mar 14
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Related Topics in Radiation Oncology

Copyright © 2024 theMednet
All Rights Reserved.